Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4214 versus Neupogen with doxorubicin + docetaxel in breast cancer
2011-003399-36Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of filgrastim in breast cancer (2 arms), sponsored by Merck & Co. Primary endpoint: Duration of severe neutropenia in Cycle 1. Started Aug 2011; status: terminated.
02
Drugs
filgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-003399-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003399-36.